Cocco E

No ORCID on file · 4 papers in corpus
2025
A Radiomic-based model to predict the depth of myometrial invasion in endometrial cancer on ultrasound images.
Scientific reports ·doi:10.1038/s41598-025-00906-6

In Europe, endometrial carcinoma was found to be the fourth most common tumor in the female population in 2022. The depth of myometrial invasion is a well-established and crucial prognostic risk factor in endometrial cancer patients and is …

2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-18-0864

Purpose: Uterine serous carcinoma (USC) is a rare and aggressive variant of endometrial cancer. Whole-exome sequencing (WES) studies have recently reported c-Myc gene amplification in a large number of USCs, suggesting c-Myc as a potential …

2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Clinical & experimental metastasis ·doi:10.1007/s10585-011-9401-0

We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. We studied the expres…

2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
British journal of cancer ·doi:10.1038/sj.bjc.6605760

BackgroundUterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human…